Introduction K V 11.1 (or hERG1), encoded by KCNH2 or hERG1 (Sanguinetti et al., 1995; Trudeau et al., 1995) is the pore-forming subunit of the rapid delayed rectifying K 1 current, which is a major regulator of action potential (AP) repolarization in the human cardiac ventricle (Sanguinetti and Tristani-Firouzi, 2006) . K V 11.1 displays peculiar biophysical properties, which enable it to contribute to shaping the repolarization phase of the AP (Spector et al., 1996) . Defective K V 11.1 can slow ventricular repolarization, thus predisposing certain individuals to long QT syndrome, a prolongation of the ECG QT interval (Tseng, 2001) . Long QT syndrome can lead to arrhythmias, particularly to torsade de pointes (Viskin, 1999; De Bruin et al., 2005) . Thus, pharmaceutical companies adopt an early screening policy to test the effects of any newly developed compound on K V 11.1 currents (Sanguinetti and Mitcheson, 2005) . Such screening is mandatory for approval for clinical use. Ample evidence shows that K V 11.1 channels are often aberrantly expressed in solid human cancers (Arcangeli, 2005) as well as in leukemias (Pillozzi et al., 2002 Arcangeli et al., 2012) . K V 11.1 controls different aspects of cell malignancy, from proliferation and survival, to transendothelial migration and bloodstream invasion (Arcangeli et al., 2012) . Furthermore, in acute lymphoid leukemia (ALL), the K V 11.1 function is necessary for the development of tumor resistance to chemotherapy , as blocking K V 11.1 decreases tumor growth in mice xenografted with leukemic cells, and in particular with chemoresistant cells . ALL cells express a plasma membrane complex constituted by K V 11.1, the b1 integrin subunit and the SDF-1a receptor CXCR4. This complex mediates the protection from chemotherapeutics conferred to ALL by mesenchymal stromal cells (MSCs) . Classic K V 11.1 blockers impede complex formation and overcome chemoresistance in vivo and in vitro.
The aforementioned evidence and the observation that K V 11.1 regulates proliferation and apoptosis in other tumors (Arcangeli, 2005; Arcangeli et al., 2009; Jehle et al., 2011) indicate K V 11.1 as a potential target for antineoplastic therapy, provided that one can avoid cardiotoxic effects. A possible solution is suggested by the observation that KCNH2 expresses at least two alternative transcripts, KCNH2a and KCNH2b, coding for K V 11.1A and K V 11.1B proteins, respectively. K V 11.1B presents a shortened and distinct N terminus, constituted by 34 amino acid residues. This peculiar domain determines the faster deactivation gating typically observed in K V 11.1B (Lees-Miller et al., 1997; Morais Cabral et al., 1998) . The relative abundance of these isoforms determines the kinetic properties of the rapid delayed rectifying K 1 current (Pond et al., 2000; Jones et al., 2004; Sale et al., 2008; Larsen and Olesen, 2010) . In cardiac myocytes both isoforms contribute to the rapid delayed rectifying K 1 current although K V 11.1A tends to predominate (Pond et al., 2000; Jones et al., 2004; Sale et al., 2008; Larsen and Olesen, 2010) . On the contrary, leukemias mainly express K V 11.1B , and overexpression of the KCNH2b transcript in pediatric T-ALL identifies a patients' subgroup with a worse prognosis (Pillozzi et al., 2014) . Therefore, one possibility of circumventing the risk of developing torsade de pointes in patients treated with K V 11.1 blockers would be to selectively inhibit K V 11.1B, the leukemia-specific channel isoform (Arcangeli et al., 2012) .
CD-160130 is a novel pyrimido-indole drug with a weak phosphodiesterase-4 (PDE-4) inhibiting activity. Preliminary results suggest that this compound induces apoptosis of chronic lymphoid leukemia (CLL) cells (Weinberg et al., 2007) . We have determined the effects of CD-160130 on the K V 11.1 isoforms by using patch-clamp techniques. Additionally, the antineoplastic effects of CD-160130 on several human leukemia cell lines and primary samples have been examined by assessing its cell killing and proapoptotic properties. Finally, we evaluated the antileukemic activity of CD-160130 in vivo in an acute myeloid leukemia (AML) mouse model, and tested its effects in guinea pigs, either on the AP of acutely isolated cardiac ventricular myocytes or on ECG parameters in vivo.
Materials and Methods

Cell Culture and Treatment
Cell Culture and Transfection. Acute leukemia cell lines and MSCs were cultured as previously described . MSC co-cultures were established as in . The MEC1 cell line was maintained in Iscove's modified Dulbecco's medium with 5% heat-inactivated fetal bovine serum. Human Embryonic Kidney 293 (HEK 293) cells were cultured and transfected with different vectors (see Supplemental Material) as previously reported . Chinese hamster ovary cell lines were cultured and transfected as in Guasti et al. (2008) . L 929 cells were cultured and transfected as in Zimin et al. (2010) , except that LipofectAMINE 2000 (Invitrogen, Carlsbad, CA) was used for transfection. For electrophysiology, the adherent cells were harvested using 0.25% trypsin/EDTA (Invitrogen).
Leukemic B and Peripheral Blood Mononuclear Cell (PBMNC) Isolation. Leukemic B cells were purified using the RosetteSep human B cell enrichment cocktail (STEMCELL Technologies, Vancouver, Canada) and the Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) density gradient centrifugation. Cells were resuspended as in Levesque et al. (Levesque et al., 2001) . PBMNCs were isolated from buffy coat preparation of two independent healthy donors, using the FicollHypaque gradient centrifugation. Mononuclear cells were recovered at the interphase, washed, counted, and then used in the viability experiments.
Clonogenic Assay
Bone marrow (BM) aspirates from patients in complete remission were obtained from the Oncohematology Laboratory of the Department of Woman and Child Health, University of Padova (under informed consent). BM cells were cultured on MethoCult GF H4034 (STEMCELL Technologies), designed to support growth of colony forming units (CFUs) CFU-GEMM, CFU-GM, CFU-G, CFU-M, and CFU-E, and the burst forming unit BFU-E colonies, by testing two different CD-160130 concentrations (5 and 10 mM). CD-160130 was preincubated with 2 Â 10 4 BM cells/35 mm dishes for 15 minutes. Cells were then maintained in a humidified atmosphere and 5% CO 2 . Colonies were enumerated using an inverted microscope after 18 days of culture according to the manufacturer's protocol. The results were the average of three independent experiments from three different patients.
Cell Viability, Cytotoxicity, and Proliferation. To assess cell viability the WST-1 cell viability assay (Roche Diagnostics, Mennheim, Germany) was used. Leukemia cells were serum starved for 16 hours with 1% fetal bovine serum and were subsequently seeded at 3 Â 10 4 /well in 96-well plates, and incubated with CD-160130 for 24 hours. PBMNCs were seeded (6 Â 10 4 /well) in 96-well plates, and incubated with CD-160130 for 6 hours without stimulation. In both cases at the end of incubation the WST-1 reagent was added and absorbance was measured at 450 nm. The mean and S.D. were calculated for each group and average data fitted using a Hill-type equation (see Supplemental Material). The ED 50 value was calculated from the dose-response curve interpolating the experimental data (Microcal Origin 8.0 software; OriginLab Corporation, Nothampton, MA). For the cytotoxicity assay CLL cells (2.5 Â 10 5 /well) were seeded in 96-well plates and incubated with CD-160130 (0.1-100 mM) for 72 hours. Cytotoxicity was detected using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay kit (Promega, Madison, WI). Optical densities were measured at 490 nm. The EC 50 value was determined from a two-point linear regression of the two concentrations of CD-160130 that induced greater than and less than 50% CLL cell death. The EC 50 was the concentration on the linear regression curve that corresponded to 50% viability. To assess cell proliferation 1 Â 10 4 cells/well were seeded in 96-well plates and treated with CD-160130 at time 0 (single treatment) or at both time 0 and 48 (double treatment). Following incubation, cells were harvested and counted using a Bürker chamber with viable cells identified as trypan blue negative.
Electrophysiological Experiments
Patch-Clamp Recording. Membrane currents were recorded in the whole-cell configuration of the patch-clamp technique at room temperature (about 25°C) by using a Multiclamp 700A amplifier (Molecular Devices, Sunnyvale, CA). Micropipettes (3-5 MV) were pulled from borosilicate glass capillaries (Harvard Apparatus, Holliston, MA), with a PC-10 pipette puller (Narishige, Tokyo). Series resistance was always compensated (up to approximately 80%). Currents were lowpass filtered at 2 kHz and digitized online at 10 kHz, with Digidata 1322A and pClamp 8.2 (Molecular Devices, Sunnyvale, CA). Data were analyzed off-line with pClamp and Origin 8.0 (Microcal, Inc., Northampton, MA) software. To measure K V 11.1, K ir 2.1, and K V 1.5 currents, the pipette solution contained (in mM): K 1 aspartate 130, NaCl 10, MgCl 2 2, CaCl 2 2, HEPES 10, and EGTA 10, titrated to pH 7.3 with KOH. During the experiments, cells were perfused with an extracellular solution containing (in mM): NaCl 130, KCl 5, CaCl 2 2, MgCl 2 2, HEPES 10, and Glucose 5, adjusted to pH 7.4 with NaOH. In this case, the K 1 equilibrium potential (E K ) was 280 mV. When necessary, a high extracellular [K 1 ] (40 mM) was applied to increase the amplitude of inward K V 11.1 currents measured at 2120 mV, thus avoiding the necessity of applying excessively negative potentials. In this case, the NaCl and KCl concentrations were 95 and 40 mM, respectively (E K 5 230 mV). To measure the K Ca 3.1 and K V 1.3 currents, the pipette and extracellular solutions were prepared as in and Zimin et al. (2010) , respectively. The current-voltage relationship for K V 11.1 was determined from peak tail currents at 2120 mV (for 1.1 second), following 15 second conditioning potentials from 0 to 270 mV (10 mV steps). The time between consecutive trials in the same stimulating protocol was 4 seconds. The holding potential (V H ) was 0 mV. The same stimulation protocol was used to determine the concentration-response relationships for CD-160130, CD-140793, and E4031. For clarity, in Fig. 2 , B-D, we only reported the drug effect on the tail currents elicited after conditioning at 0 mV. The currentvoltage relationships were determined for K ir 2.1 from measurements of peak current amplitude at 2110 mV (for 500 milliseconds). For K V 1.3 and K V 1.5 the current-voltage relationships were determined from measurements of peak current amplitude at 140 mV (for 500 milliseconds), starting from a V H value of 280 or 260 mV, respectively. The K Ca 3.1 currents were elicited by voltage ramp protocols as in ) and the decrease of slope conductance was taken as a measure of channel block. Each compound was applied for at least 4 minutes (or until steady-state inhibition was attained), with each concentration being tested on at least five different cells. At the end of each application, drugs were washed out for at least 2 minutes. As positive controls, we used E4031 (for K V 11.1), 100 mM BaCl 2 (for K ir 2.1), 50 mM nifedipine (for K V 1.5), 10 nM margatoxin (for K V 1.3), and 25 nM TRAM-34 (for K Ca 3.1). Dimethylsulfoxide (DMSO), which served as the solvent for CD-160130 and CD-140793, was used as the negative control.
Perforated Patch Recordings of Cardiac Myocyte APs. Borosilicate standard wall without filament glass electrodes (Harvard Apparatus) were pulled to a resistance of 1.5-2.5 MV. Electrodes were tip-filled (2-3 mm) with amphotericin-B-free solution and back-filled with intracellular pipette solution containing 0.48 mg/ml amphotericin-B (Apollo Scientific, Stockport, United Kingdom). Current-clamp recordings were made using an Axopatch 200B amplifier, Axon 1322A digidata, and Clampex 8.2 (Molecular Devices, Sunnyvale, CA). APs were stimulated at 2 Hz in modified extracellular solution (4 mM KCl, 1 mM MgCl 2 ) and at 37°C. APs were sampled at 10 kHz and on-line filtered at 5 kHz. 20 APs were signal averaged after stabilizing in the control or CD-160130-containing Tyrode.
Analysis of Electrophysiological Experiments. The concentrationresponse relationships for the different drugs were obtained by plotting the percentage residual currents versus the drug concentration. The residual currents were calculated through the following formula: 100×ðI max drug =I max contr Þ, where I max drug is the maximal current in the presence of a given drug concentration and I max contr is the maximal current in the absence of the drug; for K V 11.1 the maximal tail current is the current at peak subtracted from the holding current. The mean and S.E.M. were then calculated for each drug concentration and the average data points fitted using a Hilltype equation, y 5 A 0 1 ½ðA 0 2 A 1 Þx n =k n 1 x n , where A 0 is the minimum and A 1 is the maximum of the function; x is the drug concentration; k is the IC 50 value; and n is the Hill coefficient. The IC 50 value was calculated from the concentration-response curve interpolating the experimental data using the Microcal Origin software; OriginLab Corporation.
In Vivo Experiments
The in vivo experiments on mice and guinea pigs are extensively described in the Supplemental Material. All experiments on live vertebrates have been carried out in accordance with the Principles of Laboratory Animal Care (directive 86/609/ EEC). Fig. 2 . CD-160130 and E4031: K V 11.1 blockers with different isoform selectivity. (A) Typical K V 11.1A and K V 11.1B currents in stably transfected HEK 293 cells and the effect of the selective K V 11.1 inhibitor E4031 and CD-160130. The inset shows the protocol used to record the tail current. The main functional difference between the two isoforms consists of the more rapid deactivation kinetics of K V 11.1B, which is apparent when comparing the upper (K V 11.1A) and the lower (K V 11.1B) panels in Fig. 1A . Both currents were fully blocked by 2 mM E4031, a class III antiarrhythmic drug considered the prototype of K V 11.1 blockers. (B) Concentration-response curves and IC 50 values obtained with E-4031 on transfected HEK 293 cells. At both 50 and 100 nM, no significant difference was observed between the effects produced on K V 11.1A or K V 11.1B (P = 0.407 and 0.426, respectively; n = 6). (C) Concentrationresponse curves and IC 50 obtained with CD-160130 on transfected HEK 293 cells. Full concentration-response relationships were obtained for both E4031 and CD-160130 by measuring the percentage residual tail currents at different drug concentrations, after a 15 second pulse at 0 mV. The applied protocol is shown in the inset in (A) and detailed in Materials and Methods. (D) Bars give K V 11.1 residual current in the presence of CD-160130 (50 mM), CD-140793 (50 mM), and DMSO. A significant difference was found between inhibition of K V 11.1A and K V 11.1B with both compounds (P , 0.01 for CD-160130 and P , 0.01 for CD-140793; n = 6), although the degree of inhibition was higher in the CD-160130 group. DMSO, used for the solubilization of CD-160130 and CD-140793, produced no effect on either K V 11.1 isoform at the maximum concentration used (1% v/v) . (E) Concentration-response relationships obtained with CD-160130 on cells transfected with K ir 2.1 (solid stars), K V 1.3 (open circles), K V 1.5 (solid circles), or K Ca 3.1 (solid squares). For K ir 2.1 we measured the percentage residual steady-state currents at different drug concentrations at 2110 mV (V H was 270 mV). For K V 1.3 we measured the percentage residual currents at different drug concentrations at +40 mV (from a V H of 280 mV) following the procedures as in Zimin et al. (2010) . For K V 1.5 we measured the percentage residual currents at different drug concentrations at +40 mV (from a V H of 260 mV). K Ca 3.1 currents were elicited by voltage ramps from 2120 to +50 mV (from a V H of 280 mV). The fold decrease of slope conductance was taken as a measure of channel block. For K V 1.5, K Ca 3.1, and K ir 2.1 HEK transfected cells were analyzed; for K V 1.3, L929 cells were used.
Chemicals and Drugs
CD-160130 and related analogs were synthesized as in Reichelt et al. (2014) . Stock solutions (5 and 10 mM) of CD-160130 and CD-140793 (BlackSwanPharma GmbH, Leipzig, Germany) were prepared in DMSO for in vitro experiments. The maximal DMSO concentration for in vitro experiments was 1% v/v. In particular, for patch-clamp experiments the effects of DMSO on the currents were subtracted from the effects of CD-160130 at the highest tested concentration. For ECG measurement, CD-160130 (10 mg/kg) was suspended in 5% Kolliphor in 0.9% NaCl. Ora-Plus (Paddock Laboratories, Inc., Minneapolis, MN) was used as the vehicle for oral gavage administration of CD-160130 in mice experiments.
Amphotericin B (60 mg/ml) was dissolved in DMSO. E4031 (Alomone Laboratories, Jerusalem, Israel) was dissolved in water (stock solution of 5 mM). Stock solution of cytarabine, doxorubicin (Amersham, GE Healthcare Pittsburgh, PA; 50 mg doxorubicin chlorohydrate in NaCl, pH of 3) and fludarabine used in the co-culture experiments were prepared in distilled water. Sotalol, used for the ECG measurement was dissolved in 0.9% NaCl. Unless otherwise indicated, chemicals were purchased from Sigma Chemicals (St Louis, MO).
Statistical Analysis
All averaged data are presented as mean 6 S.E.M. (or S.D. when specified).The statistical significance of differences between experimental groups was calculated with the Mann-Whitney test, with a P , 0.05 being considered as statistically significant. When specified (see the legends to Fig. 5D and Fig. 7 , B and C), the Student's t test was applied.
Information concerning guinea pig cardiac myocyte isolation, astemizole binding assay, PDE-4 inhibition assay, apoptosis analysis, bromodeoxyuridine assay, RNA interference, real-time quantitative polymerase chain reaction, Western blot, vectors, and in vivo experiments (pharmacodynamics, pharmacokinetics, and ECG recordings) are detailed in the Supplemental Material. Written informed consent was obtained from all patients (mixed sex) or their legal guardians prior to sample collection, according to the Declaration of Helsinki.
Results
Pharmacological Properties of CD-160130. The pyrimidoindole CD-160130 was originally developed as a PDE-4 inhibitor with the aim of developing a drug able to promote apoptosis in leukemic cells through an increase in intracellular cAMP levels (Kim and Lerner, 1998; Lerner and Epstein, 2006) . Indeed, CD-160130 was shown to possess a cytotoxic effect on primary CLL cells (Weinberg et al., 2007) . However, discrepancies between the PDE-4 inhibitory activity and cytotoxic efficacy for CD-160130 and some of its close analogs emerged (see Supplemental Table 1 ), suggesting that the inhibition of PDE-4 is unlikely to play a major role in these effects. Supplemental Table 1 also shows that several of these compounds also bind K V 11.1 channels expressed in HEK 293 cells, as measured by the astemizole binding assay. As is evident from Fig. 1 , K V 11.1 binding efficacy better correlated with CLL cell killing than PDE-4 inhibition. In particular, CD-160130 had the highest K V 11.1 binding affinity (B 50 5 1.89 mM; Supplemental Table 1 ) and the highest current blocking effect. This was correlated with a high cytotoxic capacity and yet low PDE-4 inhibition. In contrast, CD-140793 (a structural analog of CD-160130, which differs by a single substitution in the R4 position of the molecule) did not bind K V 11.1 and did not show any antileukemic effect, despite displaying similar inhibitory activity on PDE-4 (Supplemental Table 1 ). These data prompted us to evaluate whether the effect of CD-160130 on leukemic cells was caused by a blocking effect on K V 11.1 currents.
CD-160130 Blocks K V 11.1 Currents. Leukemia cells express the A and B isoforms of K V 11.1, but tend to overexpress K V 11.1B Pillozzi et al., , 2014 ). Hence, we tested the effect of CD-160130 on either isoforms, expressed in HEK 293 cells (Fig. 2 ). Currents were measured as tail currents at 2120 mV, after depolarizing voltage steps ranging from 0 to 270 mV and lasting 15 seconds ( Fig. 2A, inset) . The classic K V 11.1 blocker E4031 produced similar effects on both channel isoforms (Fig. 2B ). On the other hand, CD-160130 had a 7.6-fold higher selectivity for K V 11.1B (IC 50 5 1.8 6 0.26 mM; Hill coefficient 5 0.88 6 0.25) than for K V 11.1A (IC 50 5 13.4 6 3.0 mM; Hill coefficient 5 1.1 6 0.1) (Fig. 2C) . The difference between the IC 50 values was statistically significant (at 1 mM, P , 0.01; n 5 6). As shown by the data on N-deleted mutants (Supplemental Fig. 1 ), the different efficacies of CD-160130 and E4031 on the two K V 11.1 isoforms did not depend on the peculiar Kv11.1B N-terminal domain (Supplemental Fig. 1 ).
As expected, CD-140793 produced negligible (on K V 11.1A) or small (on K V 11.1B) current inhibition, even at very high concentrations (50 mM; Fig. 2D ). Nonetheless, both CD-160130 and CD-140793 produced significantly stronger inhibition of K V 11.1B (P , 0.01; at 50 mM; n 5 6). (A and B) currents elicited in the G628C:S631C K V 11.1 mutant and effects of 1 mM E4031 and 10 mM CD-160130. (C) K V 11.1 current inhibition by E4031 and CD-160130 at the two tested potentials (+40 and 280 mV); for E4031 the difference between the inhibition at +40 and 280 mV was not statistically significant (P . 0.05; n = 5), while a significant difference was obtained for CD-160130 (P , 0.05; n = 9).
K V 11.1B Inhibitor in Leukemia
We also evaluated the effects of CD-160130 on other K 1 channels known to be expressed in lymphoid or myeloid cells, such as K ir 2.1, K V 1.3, K V 1.5, and K Ca 3.1. These were expressed in HEK 293 cells (Fig. 2E ). CD-160130 produced only 12% inhibition of K ir 2.1 currents at 100 mM, while it inhibited K V 1.3, K V 1.5, and K Ca 3.1 in a dose-dependent manner (the IC 50 values were 36.7 6 5.7, 26.05 6 6.25, and 53.5 6 7.05 mM, respectively).
Kinetics and Voltage Dependence of Channel Inhibition. At the maximum concentrations of CD-160130 tested, the current inhibition was reversed after 258 6 20 seconds of washing (n 5 5). This is different from what we normally observe with E4031, whose block is notoriously difficult to reverse by washout (Faravelli et al., 1996) , and suggests that the blocking mechanism of CD-160130 is different from that of E4031. This was further investigated by testing the CD-160130 effect on the non-inactivating G628C: S631C K V 11.1 mutant. The absence of channel inactivation enabled us to (1) study the kinetics of channel block and (2) compare the effects of outward and inward ion fluxes on the CD-160130 potency. In these measurements, E K was set to 230 mV, to make it practical to compare inhibition of both outward and inward currents. Currents were elicited, from a V H of 280 mV, by a 120 second step to 140 mV. Next, V m was stepped back to 280 mV, to reveal the inward tail currents. Either CD-160130 (10 mM) or E4031 (1 mM) was applied after the current had reached steady state at 140 mV. Typical current traces are shown in Fig. 3A . For clarity, the tail currents at 280 mV are magnified in Fig. 3B . In a series of representative experiments carried out in the same batch of cells, CD-160130 took about 7.4 6 1.25 (n 5 6) s to start . *** = P , 0.001; **= P , 0.01. A significant difference was also found between the effects of E4031 and CD-160130 on K V 11.1-F656A current (P , 0.01; n = 5 for E4031; n = 10 for CD-160130). blocking K V 11.1 current at 140 mV. In contrast, the effect of E4031 had a latency of 18 6 1.4 seconds (n 5 5; P , 0.01 compared with the CD-160130 values). We next compared the effect of the two blockers on outward (at 140 mV) and inward (at 280 mV) currents (Fig. 3C ). For E4031, inverting the current flow by reversing the V m polarity produced no significant difference in channel block (P . 0.05; n 5 5), whereas CD-160130 had a slightly more pronounced effect on inward currents (55.1 6 3.9, n 5 7, P , 0.05). Finally, the effect of CD-160130 showed negligible voltage dependence (see Supplemental Fig. 2) .
Effect of CD-160130 on the F656A-K V 11.1A Mutant. E4031 and similar drugs block K V 11.1A and K V 11.1B isoforms by binding to aromatic residues in the channel inner cavity, particularly Phe656 (Kamiya et al., 2006) . To study whether CD-160130 acts with a similar mechanism, we compared the inhibition produced by saturating concentrations of either E4031 (5 mM) or CD-160130 (100 mM) on K V 11.1A and F656A-K V 11.1A channels. As expected, E4031 almost abolished the K V 11.1A currents, while producing approximately only 25% inhibition of the F656A-K V 11.1A current (Fig. 4, A and C) . In contrast, CD-160130 produced about 98% inhibition of K V 11.1A and 75.5% inhibition of F656A-K V 11.1A (Fig. 4 , B and C). Detailed statistics are given in the legend to Fig. 4 . These results suggest that Phe656 is not part of the main binding site for CD-160130.
Effect of CD-160130 on Leukemia Cell Vitality and Proliferation. To verify whether CD-160130 also blocked K V 11.1 in leukemia cells we used FLG 29.1, an AML cell line that mainly expresses the K V 11.1B isoform , see the inset to Fig. 5A ). As shown in Fig. 5A , the IC 50 obtained for CD-160130 on FLG 29.1 cells (1.34 6 0.24 mM) was very similar to that obtained on HEK 293 cells transfected with K V 11.1B, supporting the notion that CD-160130 exhibits isoform selectivity.
Next, we investigated the effects of CD-160130 (0.1-50 mM) on FLG 29.1 cell viability, evaluated by either WST-1, trypan 1A and 1B values were average expression of a cohort of T-ALL patients.
K V 11.1B Inhibitor in Leukemia blue, or bromodeoxyuridine assay. Since the three assays gave virtually identical results (Supplemental Table 2 ), we will only show the data obtained with the WST-1 assay ( Fig. 5B ; Tables 1,  2 and 3 ). FLG 29.1 cell viability was markedly reduced by CD-160130 at micromolar concentrations (Fig. 5B ). The effective dose (ED 50 ) turned out to be 3.48 mM ( Fig. 5B ; Tables 1-3) . Conversely, CD-140793, which does not block K V 11.1 currents, produced little effect on FLG 29.1 even at high concentrations (50 mM; Fig. 5C ). To test whether the effect of CD-160130 on FLG 29.1 was related to the blocking of K V 11.1, we silenced KCNH2 with small interfering RNAs (siRNAs). Since FLG 29.1 cells almost exclusively express K V 11.1B , the siRNAs we used, which target a KCNH2 sequence common to both KCNH2a and KCNH2b, and indeed silenced KCNH2b in these cells. Compared with scrambled siRNAs, anti-K V 11.1 siRNAs reduced the K V 11.1 current density of FLG 29.1 and the number of viable cells by roughly the same extent (55%) 48 hours after transfection (Fig. 5D) . Moreover, the ED 50 of CD-160130 on anti-K V 11.1 siRNA-treated cells was 15.6 mM (Fig. 5E ). A significant difference in the percentage of viable cells was detected at 10 mM (P , 0.01, n 5 9; inset to Fig. 5E ). As expected, scrambled siRNA had virtually no effects on CD-160130 ED 50 (Supplemental Fig. 3 ). These results are consistent with CD-160130 reducing the viability of FLG 29.1 cells through a Kv11.1B-dependent mechanism. The isoformnonselective K V 11.1 blocker E4031 reduced FLG 29.1 cell viability, although with a significantly higher ED 50 (55.7 mM; Fig. 5F ). It is worth noting that E4031 was efficacious at concentrations comparatively high relative to those required to block the channel (Fig. 2B ). This is normally observed when using this drug and is caused by a lower free concentration in complex, protein-rich, media (Masi et al., 2005) . The effect of CD-160130 on the viability of further leukemia cell lines and primary samples (either AML or ALL) is shown in Table 1 . CD-160130 turned out to be cytotoxic toward different leukemia cells in the micromolar range. CD-160130 did not affect cell viability of either normal PBMNC or EpsteinBarr virus-infected B lymphocytes (Tables 2). We also evaluated whether CD-160130 displayed BM toxicity by testing the compound on the clonogenic potential of BM cells from three healthy donors. CD-160130 did not affect either the number of CFUs, or the percentage of different CFUs at 5 mM concentration, but only produced a weak, not statistically significant, reduction in the overall number of colonies at 10 mM (Tables 3). Collectively, the cytotoxic effect of CD-160130 was more evident when more KCNH2b transcript (measured by realtime quantitative polymerase chain reaction) was expressed by leukemic cells. Consistently, a good relationship emerged between the efficacy of CD-160130 and the amount of K V 11.1B protein ( Supplemental Fig. 4) . In contrast, the K V 11.1A-expressing HCT116 colorectal cancer cells were less sensitive to CD-160130 (ED 50 11.9 mM, Table 2 ).
We also studied the effects of CD-160130 on CLL primary samples, similar to those analyzed in Fig. 1 , to determine whether the effect was related to a specific mutation status (Table 4 ). CLL cells express K V 11.1 (Smith et al., 2002) , and the expression of the KCNH2b transcript (Supplemental Table 3 ) and of the K V 11.1 current (Supplemental Fig. 5 ) was confirmed in the MEC1 cell line. As previously reported (Weinberg et al., 2007) , CLL cells were sensitive to the drug. CD-160130 was more efficacious on CLL samples deleted both in 13q and 11q, which responded poorly to fludarabine (Table 4) .
Finally, we evaluated whether CD-160130 inhibited leukemia cell proliferation. After a single treatment, leukemia cell proliferation was completely abolished at concentrations above 5 mM (Fig. 6A) . The effect was more evident on 697 and REH, where concentrations between 1 and 5 mM were also efficacious. At lower concentrations, after an initial block (lasting about 24 hours), FLG 29.1 and HL60 cells started to proliferate again. The effect was potentiated by subsequent readministration. For example, when CD-160130 was readded to the cells after 48 hours, the inhibition of cell proliferation was sustained (in FLG 29.1, Fig. 6B ) or complete (in HL60, Fig.  6B ). Under these conditions, even 0.1 mM produced a significant reduction of cell proliferation. This is consistent with the pharmacokinetics of CD-160130 in vivo and the antileukemic effects in vivo, as will be discussed below.
Effect of CD-160130 on Leukemia Cell Apoptosis and Related Signaling. Next, we studied whether the cytotoxic effect of CD-160130 on leukemia cells was, at least in part, related to apoptosis. This point was determined on leukemic Results of the overall colony numbers obtained with clonogenic assay of three samples of healthy bone marrow treated with two different concentrations of CD-160130 (5 and 10 mM) are reported. The different colony fractions (CFU-GEMM, CFU-GM, CFU-G, CFU-M, CFU-E and BFU-E) for each group are reported. All the data were average 6 S.E.M.
Total CFU Number
Control 100 5 6 1 1 9 . 56 2.5 15 6 3 3 1 6 3 7 6 1 22.5 6 1.5 CD-160130 (5 mM) 97 6 5.2 5.5 6 1.5 21.5 6 2.5 14 6 3 2 8 . 5 6 2.5 6.5 6 0.5 24 6 2 CD-160130 (10 mM) 75 6 8.8 4 6 1 1 8 6 1 1 3 6 3 2 5 6 1 9 6 0 3 1 6 1 BFU, burst forming unit.
cells co-cultured with MSCs . For this purpose we tested 5 mM CD-160130 on either leukemic cell lines or primary samples (Fig. 7) . In primary samples, K V 11.1 expression was evaluated by flow cytometry as in (the mean fluorescence intensity data, MFI, are reported in Fig. 7 , B and D). CD-160130 induced leukemia cell apoptosis on both suspended cells and cells cultured onto MSCs. As previously reported , MSCs protected leukemia cells from the apoptosis induced by either chemotherapeutic drugs or CD-160130. Moreover, CD-160130 was able to overcome the MSC-induced chemoresistance. In primary samples, the proapoptotic effect of CD-160130 generally correlated with K V 11.1 expression.
In NB4 leukemic cells, interaction with MSCs is known to trigger the Akt/GSK3b and ERK1/2/STAT3 pathways (Tabe et al., 2007) . On the other hand, we previously showed that in 697 cells MSCs stimulate phosphorylation of ERK1/2 and Akt . CD-160130 turned out to modulate both signaling pathways (Fig. 8, A and B; Supplemental Fig. 6 ) in these cell lines. To demonstrate that the effects of CD-160130 on cell signaling were related to its action on K V 11.1B, we analyzed FLG 29.1 cells treated with K V 11.1 siRNAs. CD-160130 significantly inhibited ERK1/2 phosphorylation after 30 and 60 minutes of treatment (Fig. 8C, left panel) . Consistently, K V 11.1 silencing produced a significant decrease of pERK1/2, measured after 60 minutes of incubation. The addition of CD-160130 to K V 11.1-silenced FLG 29.1 cells did not produce any further effect on pERK1/2 (Fig. 8C, right panel) .
Effect of CD-160130 on Leukemia In Vivo. Finally, we evaluated the efficacy of CD-160130 on a preclinical leukemia model, consisting of severe combined immunodeficiency mice injected i.p. with HL60 cells transfected with the firefly luciferase gene (HL60-luc2 cells). Mice were monitored weekly, and the luciferase activity signal was quantified. The overall survival was also measured. The results are reported in Fig. 9 . The administration schedules were: (1) 1 mg/Kg, daily for 14 days; (2) 10 mg/Kg, daily for 14 days; and (3) 10 mg/kg, daily for 7 days, followed by 20 mg/kg for 7 days. In all cases, CD-160130 was administered by mouth starting from day 5 (e.g., when leukemia cells started to engraft, Fig. 9A ). The rationale for such a treatment schedule relied on biodistribution data (Fig. 9D) showing that (1) administration of 10 mg/Kg gave rise to a peak plasma concentration of around 4 ng/ml (11 nM) after 2 hours; (2) 20 mg/Kg gave rise to a peak plasma concentration of around 12 ng/ml (31 nM) between 2 and 4 hours; and (3) 1 mg/Kg was not effective. The details and statistics are given in Supplemental Table 4 . The effects of CD-160130 were compared with those observed in mice treated with Ora-Plus (Paddock Laboratories) or with the chemotherapeutic drug cytarabine. CD-160130 effectively reduced the leukemia burden in a dose-dependent manner (Fig. 9B) . In particular, at 
10 mg/kg the leukemia progression was comparable to, or even slower than, that occurring in the mice group treated with cytarabine ( Fig. 9, A and B) . No improvement was observed by increasing the dosage of the drug to 20 mg/Kg. The treatment at 10 mg/kg also improved mice survival, with survival times longer than those obtained with cytarabine ( Fig. 9C) . Effect of CD-160130 on Cardiac Physiology. One of the major hindrances for considering K V 11.1 as a therapeutic target in oncology is the cardiac side effects that many K V 11.1 blockers exert (Redfern et al., 2003; Raschi et al., 2008) . Such effects mainly consist of a lengthening of the cardiac AP (cAP), which is reflected in the lengthening of the ECG QT interval. First, we registered the ECG in mice treated with 10 or 20 mg/kg CD-160130 ( Fig. 9E ; Supplemental Table 5 ). No alterations of either the heart rate or the compensated QT interval were observed. The compensated QT interval was also not affected after 2 weeks of chronic daily administration ( Fig. 9F ; Supplemental Table 6 ).
Next, we tested the QT liability of CD-160130 by measuring its effects on the cAP stimulated in acutely isolated left ventricular guinea pig cardiomyocytes recorded at physiologically relevant temperatures (i.e., at 37°C). Guinea pig myocytes were chosen because (unlike those of smaller rodents) they exhibit cAP features similar to those observed in humans, i.e., a long depolarized cAP plateau and heavy reliance on delayed rectifier potassium currents. CD-160130 failed to lengthen the AP duration (Fig. 10A ). In particular, 1 mM CD-160130 shortened AP duration at 90% repolarization by less than 1 millisecond (20.8 6 2.3 milliseconds, n 5 7), while 10 mM CD-160130 lengthened AP duration at 90% repolarization by 2.7 6 7.4 milliseconds (n 5 6). Additionally, we analyzed the effects of CD-160130 on ECG parameters of anesthetized guinea pigs, an accepted in vivo model for the evaluation of 22 mM) , doxorubicin (0.1 mg/mL), or CD-160130 (5 mM) for 48 hours. The effects of the treatment were evaluated on early apoptosis (annexin + propidium iodide 2 cells). K V 11.1 expression in primary samples, evaluated by flow cytometry using the anti-K V 11.1 antibody, is reported as the mean fluorescence index (MFI). The MFI of BCP-ALL1 was 20, while the MFI for BCP-ALL2 was 32. FLG 29.1, HL60, and NB4 cell lines (C) and two representative AML primary samples (D) were cultured with or without MSCs (suspension) and treated with LD 50 doses of either cytarabine (45 nM) or CD-160130 (5 mM) for 48 hours. The MFI of AML1 was 150, while the MFI for AML2 was 27. The values of the untreated controls are reported as dotted bars in each graph. Statistical analysis for the data in panels (A) and (C) was carried out with the Mann-Whitney test; statistical analysis for the data in panels (B) and (D) was carried out with the Student's t test (*P , 0.05; **P , 0.01; ***P , 0.001).
drug cardiotoxicity (Morissette et al., 2013) . In these experiments, we injected CD-160130 i.v. at 10 mg/kg in a proper vehicle. CD-160130 did not produce any significant QT prolongation (Fig. 10B) up to 15 minutes after administration. The raw data, relative to either CD-160130, sotalol, or the vehicles, up to 60 minutes of infusion, are given in Supplemental Table 7 . As a positive control, we used sotalol (3 mg/Kg, i.v.), which increased the compensated QT interval by approximately 10%, as expected (Hauser et al., 2005) .
Discussion
CD-160130 is a pyrimido-indole compound, initially developed as a PDE-4 inhibitor with the aim of inducing leukemia killing. In fact, micromolar concentration of CD-160130 reduced cell viability both in leukemia cell lines and primary leukemia samples (Tables 1-4 ). In the latter, the effect of CD-160130 was more evident in the harder to treat cases, such as T-ALL and double-deleted CLL. However, cytotoxicity turned out to be not a result of PDE-4 inhibiting ( Fig. 1; Supplemental Table 1 ). An alternative hypothesis is that the antileukemic effect of CD-160130 depends on K V 11.1 inhibition, as suggested by the effect we observed with anti-K V 11.1 siRNAs. In agreement with this notion, CD-160130 turned out to block K V 11.1 channels. Also, CD-160130 displayed properties of channel block considerably different from those shown by classic K V 11.1 blockers, such as the type III antiarrhythmics. In fact, CD-160130 inhibited K V 11.1B with a 7.6-fold higher potency, compared with K V 11.1A, and strongly inhibited K V 11.1 almost independently of Phe656, which is the main binding site of type III antiarrhythmics, such as E4031. The fact that CD-160130 is somewhat less efficacious in blocking F656A K V 11.1 compared with the wild-type channel probably depends on alterations produced on the pore structure by the nonconservative F656A substitution. Nonetheless, the striking difference between the actions of E4031 and CD-160130 on F656A K V 11.1 suggests that either Phe656 makes a minor contribution to the inhibitory effect of CD-160130 or the F656A mutation has an allosteric effect on CD-160130 binding.
Successful treatment of acute and chronic leukemias is often impeded by the development of resistance to cytotoxic drugs, either at the initial presentation or following relapse (Pui and Evans, 2006) . We showed in ALL that the chemoresistance triggered by MSCs in the BM microenvironment is overcome by blocking K V 11.1 channels . In this paper, we showed that CD-160130 strongly inhibited the leukemia burden in an AML mouse model and significantly prolonged mice survival; the response was even better than cytarabine, a classic chemotherapeutic drug used in AML. The effect was evident with a schedule of daily oral administrations of 10 mg/Kg, which corresponds to plasma-free concentrations of approximately 12 nM. This concentration is lower than the IC 50 for K V 11.1 obtained from patch-clamp experiments. For CD-160130, a plasma-free concentration of 12 nM would block approximately 15% of the channels if they were activated by the acute application protocol used in Fig.  4A . We hypothesize that, considering also the slow kinetics of CD-160130 unbinding, the sustained presence of the drug in plasma produces cumulative inhibition by progressively removing increasing fractions of K V 11.1 channels from the steady-state open-close equilibrium, thus making them unavailable to open. Consistently, when we tested the effects of CD-160130 on leukemia cell proliferation in vitro, we observed that when the drug was applied only once at the lower concentrations, after an initial block (lasting about 24 hours), FLG 29.1 and HL60 cells started to proliferate again. However, the effect was potentiated by subsequent readditions, e.g., when CD-160130 was reapplied to the cells after 48 hours, the inhibition of cell proliferation was sustained (for FLG 29.1, Fig.  6B ) or complete (for HL60, Fig. 6B ). In these conditions, even 0.1 mM produced significant reduction of cell proliferation. This is also in agreement with recent results by Pier et al. (2014) showing that nonsaturating concentrations of hERG1 blockers need to be applied for long periods of time to fully produce their antitransformation effects. Although different leukemia models and different administration schedules (e.g., twice per day) could be tested, our in vivo data indicate that CD-160130 is On the whole, K V 11.1 would seem an attractive target for antineoplastic therapy, particularly in leukemias. However, K V 11.1 is normally considered as an antitarget, since blocking K V 11.1 can lead to serious cardiac side effects (Redfern et al., 2003; Raschi et al., 2008) . The present results suggest that CD-160130 could be a first-in-class K V 11.1 channel Pharmacokinetics of CD-160130 (ng/ml) analyzed in the plasma of CD1 mice after a single oral administration (10 or 20 mg/kg). Blood samples were collected at different time points (at least n = 2) and analyzed by high-performance liquid chromatography (see Supplemental Material). Two more mice were administered with a single dose of CD-160130 (1 mg/kg). Blood was collected 2 and 4 hours postoral gavage, corresponding to the higher registered values of plasma concentration for the doses previously tested. In both cases CD-160130 plasma concentration was undetectable (open circles). (E) ECG parameters of CD-1 mice at different time points after acute administration of CD-160130 (10 mg/Kg, left panel) and CD-160130 (20 mg/Kg, right panel): ECG results consisting of heart rate (HR, dashed lines) and HR compensated QT (QTc) intervals are shown (bars). The QTc interval was calculated by applying Bazett's formula (Mitchell et al., 1998) 
(F) ECG parameters in mice after chronic administration of CD-160130 (T-10, 10 mg/Kg for 14 consecutive days or T-sc, 10 mg/Kg for seven days followed by 20 mg/Kg for another seven days) in CD-1 mice: ECG results consisting of QTc intervals are shown. Experimental details are widely described in the Supplemental Material.
inhibitor appropriate for the treatment of leukemias since it overcame the chemoresistance induced in vitro by cell interaction with MSC and tightly controlled the leukemia burden in vivo, but without significant QT liability in guinea pigs. One possible explanation for these results is that because leukemia cells overexpress the K V 11.1B isoform of K V 11.1 Pillozzi et al., , 2014 , compared with cardiac cells (Pond et al., 2000 , Jones et al., 2004 Sale et al., 2008; Larsen and Olesen 2010) , the higher efficacy of CD-160130 on K V 11.1B could decrease the harmful effect on cardiac cells, without impairing the antileukemic effect. Another possibility is that the lack of effect of CD-160130 on the QT interval depends on the fact that this compound acts with a different mechanism from the classic class III antiarrythmic drugs. At the present stage, we cannot discriminate these mechanisms. Nonetheless, the characterization of CD-160130 opens the way to the development of compounds with a higher selectivity for the different K V 11.1 isoforms, accompanied by inhibitory action on the chemotherapy resistant leukemia forms and negligible QT liability.
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Supplemental Materials and Methods
Guinea pig cardiac myocyte isolation.
Adult male Dunkin Hartley guinea pigs (Harlan Laboratories, Blackthorn, UK) weighing 400-465 g were sedated with hypnorm (1 ml/kg) (Roche Diagnostics, Mennheim, Germany) and hypnovel (1 ml/kg) (VetaPharma Ltd, Leeds, UK) and sacrificed by cervical dislocation.
The heart was excised, and retrogradely perfused via the aorta with Ca 2+ free Tyrode for 4-6 minutes, enzyme solution (1.04 mg/ml type I collagenase, 0.62 mg/ml type XIV protease and 1.67 mg/ml bovine serum albumin) for 7-10 minutes and then with Ca 2+ free Tyrode for 1-2 minutes. Following tissue digestion the left ventricle was dissected into small pieces and mechanically agitated in 2 mM Ca2 + Tyrode to disperse single cells. Tyrode solution contained (in mM): 0 or 2 CaCl 2 ,4 KCl, 135 NaCl, 1 MgCl 2 , 0.33 NaH 2 PO 4 , 5 Na + pyruvate, 10 glucose, 10 HEPES; pH adjusted to 7.4 with NaOH. HEK 293 cells stably expressing K V 11.1 channels were maintained as outlined in Cell
Culture section with membranes being prepared as described by Finlayson et al, (Finlayson et al., 2001b astemizole (10 μM) was used to determine non-specific binding. The subsequent steps of this assay were performed as described in Finlayson et al, (Finlayson et al., 2001a) .
PDE-4 inhibition assay.
Human recombinant PDE-4A catalytic domain comprising amino acids 342-704 was expressed as previously described by Richter et al, (Richter et al., 2000) . PDE-4A activity was determined by the scintillation proximity assay (SPA) as described by the manufacturer (Amersham Biosciences, GE Europe GmbH, Munchen, Germany) and by Horton and Baxendale (Horton and Baxendale, 1995) . The reaction mixtures contained 100 mM Tris
HCl (pH 7.5), 5 mM MgCl 2 , 3.8 mM 2-mercaptoethanol, 1 µM cAMP as substrate and the inhibitors at different concentrations. The reaction was started by adding the enzyme. The operating volume was 100 µl in the wells of a 96-well plate. All test substances were produced as stock solutions in DMSO. After reaction initiation samples were incubated at 22°C for 20 minutes. The reaction was stopped by the addition of SPA bead suspension which contains the zinc sulphate concentration provided according to the manufacturer.
Afterwards, the beads were allowed to sediment for 30 minutes and the plates were analysed on a luminescence microtitre plate reader (Fluostar Optima, BMG Labtechnologies GmbH, Ortenberg/Germany).
Apoptosis Analysis.
The effects of the different compounds on leukemic cell line and primary samples apoptosis .
Western Blot (WB).
Total protein extraction were performed by standard methods using lysis buffer (Cell Signaling Technology). WBs were carried out as described in Crociani et al, . For the experiments reported in Fig. 8 , 30 µg of total lysates were used. For pAkt, pGSK3β, pERK1/2 and pSTAT3 detection, the anti-pAkt1/2/3 (Thr308)R (Santa Cruz Biotechnologies, Dallas, TX, USA, dilution 1:500), the anti-pGSK3β (Ser9) (Cell Signaling, Danvers, MA, USA, dilution 1:1000), the anti-phospho-p44/42 MAP kinase (Thr202/Tyr204) (Cell Signaling, dilution 1:500) and the pStat3 (Tyr705, D3A7) (Cell Signaling, dilution 1:500) primary antibodies were used. For tAkt, tERK and tSTAT3 detection, the anti-tAkt1/2/3 (H-136) (Santa Cruz Biothecnologies, dilution 1:500), the ERK1 (C-16) (Santa Cruz Biothecnologies, dilution 1:200) and the Stat3 (79D7) (Cell Signaling, dilution 1:1000) primary antibodies were used. Anti-rabbit peroxidase-conjugate (Sigma-Aldrich, dilution 1:10000) was used as secondary antibody. Western blotting images were acquired with an Epson 3200 scanner, and the relative bands analyzed with ImageJ 1.47v free software (developed at the National Institutes of Health). The intensity of the bands related to the phosphorylated proteins were normalized to the intensity of the bands related to the correspondent total proteins. Ratios reported in the graphs were mean ± SD of at least three different analyses. For the experiments reported in Supplemental Fig. 3 , 20 µg of total lysates were used decorated with the anti-K V 11.1 COOH-terminus primary antibody
(1:1000 dilution, developed in our laboratory (Lastraioli et al., 2004) ). The secondary antibody was anti-rabbit peroxidase-conjugate (Sigma-Aldrich, 1:10000 dilution). The intensity of the bands was normalized to the intensity of the bands that corresponds to the α-tubulin protein (Sigma-Aldrich). The control cells ratio was set as one. For each condition, at least three experiments were analyzed separately. The mean intensity of the bands for K V 11.1B was reported as arbitrary units.
In vivo experiments.
In vivo leukemia model. For the in vivo leukemic mouse model experiments, HL60 cells were transfected with firefly luciferase gene using pGL4.51[luc2/CMV/Neo] plasmid (Promega, Madison, USA). 3.5x10 6 cells were mixed with 20 ng of plasmid into a total volume of 400 µl and the mixture was transferred into 4 mm Biorad Gene Pulser cuvette, and electroporated by Gene Pulser X cell Electroporation system (Bio-Rad) using "Mammalian 12" protocol. After electroporation an appropriate amount of the complete medium was added to the cells that were rapidly re-plated into a 6 well cluster. After 24h the cells were moved into a 25 cm 2 flask and G418 was added to obtain cell selection.
The AML cell line HL60 expressing luciferase (HL60-luc2) was injected intraperitoneally Flow rate was 1.0 ml/min and eluents were A (0.1% TFA in H 2 0) and B (0.1% TFA in CH 3 CN), used in isocratic conditions of 20% of B for 16 min. Detection was performed at 340 nm by using a photo array Uv-Vis detector and the mass spectra of the eluted peaks were also recorded. The retention time for CD-160130 was about 12 min.
The calibration curve used for the HPLC quantification of the CD-160130 was calculated by using the integrated peaks area derived from standard solutions of CD-160130 dissolved in mice serum, in the range between 0.89 and 890 ng/mL. All chromatograms were elaborated and integrated with the Xcalibur software (Thermo).
ECG data acquisition and analysis. ECG were recorded with ESAOTE electrocardiograph adapted for veterinary use as in . CD-1 mice used for the determination of CD-160130 plasma concentration were also monitored by ECG registration. ECG registrations were performed in 10 anesthetized male Dunkin-Hartley guinea pig (200-300 gr). Guinea pigs were anesthetized with Pentobarbital (45 mg/kg) and then IV injected with either CD-160130 (10 mg/Kg) or sotalol (3 mg/Kg). ECG were performed at several time points starting with a registration pre-drug administration and lasting for at least one hour.
Body temperature was maintained constant through the entire experiment using an infra-red lamp. The following parameters were analyzed: heart rate (beats/minute), RR interval (msec) and QT interval (msec). The rate corrected QT interval (QTc) was calculated using ].
Vectors.
List of the vectors used in the electrophysiological experiments: pcDNA3.1 K V 11.1A, pcDNA3.1 K V 11.1B, pcDNA 3.1 K V 11.1 Δ2-370, pALTER MAX G628C:S631C K V 11.1 (Jiang et al., 2005) , pIND F656A K V 11.1 (Milnes et al., 2003) ECG registrations were performed in 12 anesthetized male Dunkin-Hartley guinea pig (200-300 gr). Guinea pigs were anesthetized with Pentobarbital (45 mg/kg) and then IV injected with CD-160130 (10 mg/Kg, n=5), sotalol (3 mg/Kg, n=5) or vehicle (5% Kolliphor in 0.9% NaCl and 0.9% NaCl alone). ECG were performed at several time points starting with a registration pre-drug administration and lasting for at least one hour. At least 8 ECG traces
were analyzed for each time point of each monitored guinea pig.
The following parameters were analyzed: heart rate (beats/minute), RR interval (ms) and QT interval (ms). The rate corrected QT interval (QTc) was calculated using Bazett's modified formula for the anesthetized guinea pig [QTc=QT/(RR)
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